ACE inhibition shows no benefit in the PEACE trial
This article has no abstract so we have provided the first paragraph of the full text.
Angiotensin-converting-enzyme (ACE) inhibitors are well established in the prevention of cardiovascular events in patients with heart failure or left-ventricular systolic dysfunction. In addition, these agents have improved outcomes in high-risk patients with vascular disease and normal left-ventricular function. The Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) trial was designed to investigate whether low-risk patients with coronary artery disease would also benefit from adding an ACE inhibitor to their usual therapy.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
